Free press releases distribution network?

More news: Health/Surgery
Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Drawbacks in Current Rheumatoid Arthritis Therapies Point to a Large Untapped Market in the U.S. Finds Frost & Sullivan - Emerging remedies must demonstrate a high degree of safety and efficacy to gain acceptance - Lifesciences.Frost.com
Drawbacks in Current Rheumatoid Arthritis Therapies Point to a Large Untapped Market in the U.S. Finds Frost & Sullivan

 

PRZOOM - /newswire/ - Mountain View, CA, United States, 2012/10/18 - Emerging remedies must demonstrate a high degree of safety and efficacy to gain acceptance - Lifesciences.Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The availability of tumor necrosis factor (TNF) inhibitors has greatly improved the pharmacological management of rheumatoid arthritis (RA). Both patients and physicians are familiar with TNF inhibitors due to their long history; however, their many limitations such as high cost, potential side effects, and injection requirement have created a need for alternative therapies. This need, along with a potentially large patient pool, is encouraging pharmaceutical and biotechnology companies with disease expertise to break into this sizeable market.

New analysis from Frost & Sullivan's (lifesciences.frost.com) United States Market for Rheumatoid Arthritis Pharmacotherapeutics research finds that the market earned revenues of more than $7.74 billion in 2011 and estimates this to reach $11.79 billion in 2017.

If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers[.]frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

RA is an incurable chronic condition that affects 2.3 million adults in the United States. Although the overall disease prevalence is not expected to change significantly, the eligible patient community is likely to grow owing to an aging population, increasing longevity, and changing clinical trends, such as new criteria for diagnosis as well as quicker identification and treatment.

"While TNF inhibitors have laid the groundwork for the next generation of effective, disease-modifying anti-rheumatic treatment and biologics, the need of the hour is patient-friendly options with improved profiles, such as oral administration or enhanced tolerability," said Frost & Sullivan Senior Industry Analyst Deborah Toscano. "These novel drugs could offer better long-term clinical outcomes."

However, slow uptake of these new drugs by a conservative regulatory and medical community is likely until they are proven in the market. To gain end-user confidence, companies must make products with a high degree of safety, with significant clinical or economic benefits over TNF inhibitors.

"Active marketing of these innovative and effective therapies will renew interest in RA drugs and increase diagnosis, fueling greater adoption and market expansion," noted Toscano.

United States Market for Rheumatoid Arthritis Pharmacotherapeutics is part of the Life Sciences Growth Partnership Services program, which also includes research in the following markets: United States Market for Ankylosing Spondylitis Pharmacotherapy, United States Market for Psoriatic Arthritis Pharmacotherapy, U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments, and United States Rheumatic Diseases Therapeutics Market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on "the next big thing" | Register: Gain access to visionary innovation

United States Market for Rheumatoid Arthritis Pharmacotherapeutics / NB33-52

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


Drawbacks in Current Rheumatoid Arthritis Therapies Point to a Large Untapped Market in the U.S. Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Britni Myers 
210-477-8481 britni.myers[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Health/Surgery Most Recent Related Press Releases:

GE Healthcare Expands Digital Maternal-Infant Care Offerings with Acquisition of Monica Healthcare
Next-generation Natural Materials to Replace Traditional Synthetic Materials in Personal Care Products Finds Frost & Sullivan
Digital Innovation-driven Diagnostic Advances Transform Smart Healthcare Finds Frost & Sullivan
Hospitals’ Outsourcing of Sterile Processing Expand Opportunities for Third Party Service Providers in the US & Western Europe Finds Frost & Sullivan
Emerging Cardiac Therapies Catalysed by Innovative Product and Next-generation Technology Finds Frost & Sullivan
Austrian Centre of Industrial Biotechnology and GE Healthcare Establish A Cell Line Engineering Collaboration
Sequencing Platform Providers Aim to Develop Tests for Infectious Diseases to Expand Market Opportunity Finds Frost & Sullivan
Arcadia Wins Top Honors from Frost & Sullivan for its Next-generation Clinical and Claims Analytics Platform, Arcadia Analytics
Vendors Favour Platform Monitoring as Novel Service Models Disrupt APAC Home Health Monitoring Market Finds Frost & Sullivan
Leader Biomedical and Urogyn Collaborate to Bring Innovative New Procedure Urolastic™ to India

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today